Neuroscience Education Institute

Neuroscience Education Institute NEI is the preeminent provider of continuing education and practice-based tools for healthcare professionals who treat patients with mental health disorders.

Thousands of clinicians consider NEI their top mental health resource for point of care answers and continuing medical education (CME). Here's why:

NEI Prescribe, our prescribing app, features over 150 psychiatric medications and has a dedicated Child and Adolescent section with in-depth coverage of the most commonly prescribed psychotropic drugs in pediatric patients. Continuously updated and with an interactive filter to search for medications based on key drug interactions and side effects, NEI Prescribe is your tool for point of care prescribing. Our two annual conferences—NEI Congress in the fall and NEI Synapse in the spring—fuse learning, quality, and entertainment into an educational experience that will empower you to provide the best possible care for your patients. We offer hundreds of online CME activities, including animations, case studies, self-assessments, and encore presentations from NEI's live events. The Master Psychopharmacology Program is an online assessment-based certificate program designed to help clinicians develop proficiency in the practice of psychopharmacology. Create a free NEI account at http://nei.global to take advantage of these resources. NEI Membership is required to access the full spectrum of resources, including the Master Psychopharmacology Program. Learn more at http://nei.global/mbroverview. Neuroscience Education Institute, An HMP Global Company

02/26/2026

Schizophrenia care is evolving, and your approach should evolve with it.

Join us for a free, half-day virtual program exploring the latest neurocircuitry insights and emerging treatment strategies designed to improve real-world patient outcomes.

Register now and elevate your clinical impact: https://nei.global/26smlfeb

In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal eske...
02/25/2026

In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression. Listen now

In this episode, Dr. Andy Cutler talks with Dr. Lisa Harding about how to choose between IV ketamine and intranasal esketamine for patients with difficult-to-treat depression.

This Saturday Morning! Discover how emerging therapies and evolving neurocircuitry insights are transforming schizophren...
02/24/2026

This Saturday Morning! Discover how emerging therapies and evolving neurocircuitry insights are transforming schizophrenia treatment. Join us for this free virtual program. Save your spot:

Join us for a free, half-day virtual program where we will explore how novel therapies and evolving neurocircuitry insights are driving new strategies to improve outcomes in schizophrenia.

The U.S. Food and Drug Administration (FDA) has approved milsaperidone for the acute treatment of manic or mixed episode...
02/21/2026

The U.S. Food and Drug Administration (FDA) has approved milsaperidone for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. Milsaperidone is a novel atypical antipsychotic and the major active metabolite of iloperidone. Read more:

The FDA has approved milsaperidone for the treatment of schizophrenia and acute bipolar I disorder (manic or mixed episodes) in adults.

The FDA has announced a significant update affecting several widely prescribed glucagon-like peptide-1 receptor agonists...
02/19/2026

The FDA has announced a significant update affecting several widely prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), requesting the removal of labeling language related to suicidal ideation and behavior for select agents used in obesity treatment. Read more

The U.S. Food and Drug Administration has announced a significant update affecting several widely prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs), requesting the removal of labeling language related to suicidal ideation and behavior (SI/B) for select agents used in obesity treatment...

The 2026 NEI Spring Congress faculty lineup is here. Join us May 1–3 in Kissimmee, Florida for three days of practical, ...
02/19/2026

The 2026 NEI Spring Congress faculty lineup is here. Join us May 1–3 in Kissimmee, Florida for three days of practical, evidence-based education covering mood and anxiety disorders, schizophrenia, emerging therapies, and more. Attend in person or via live simulcast. See the full lineup:

Meet the Speakers Headlining the 2026 NEI Spring Congress, May 1–3 in Kissimmee, Florida

ADHD is a lifelong neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity. Centanafad...
02/15/2026

ADHD is a lifelong neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity. Centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), is being developed as a once-daily extended-release treatment for children, adolescents, and adults.

Read more:

While there are many stimulant and non-stimulant options targeting dopamine and norepinephrine reuptake, centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) developed as a once-daily extended-release oral therapy for ADHD in children, adolescents, and...

Celebrate GABA-tine’s Day with savings on the education and resources that support confident, evidence-based care.For a ...
02/13/2026

Celebrate GABA-tine’s Day with savings on the education and resources that support confident, evidence-based care.

For a limited time, enjoy 10% off NEI Spring Congress, NEI Fall Congress, and new NEI Membership— all designed to support real-world psychiatric practice.

Use code GABA10 at checkout. Don’t Break Our Heart, Shop Before It Ends 👉 https://nei.global/GABA10

Offer expires 2/16/25

Celebrate GABA-tine’s Day with savings on the education and resources that support confident, evidence-based care.

Today, on International Day of Women and Girls in Science, we’re celebrating the women advancing innovation in mental he...
02/11/2026

Today, on International Day of Women and Girls in Science, we’re celebrating the women advancing innovation in mental health care.

👏 Dr. Kari Franson and Desiree Matthews, PMHNP-BC are leading the conversation on how prescription digital therapeutics (PDTs) can optimize patient functioning and outcomes alongside pharmacologic treatment.

Ready to rethink what’s possible in psychiatric care?
The Encore Presentation is now available — free to watch and eligible for CME/CE credit: 🔗 https://nei.global/enc25fa16

Dr. Kari L. Franson and Desiree M. Matthews, MSN, PMHNP-BC explore how apps and prescription digital therapeutics can help fill treatment gaps and improve patient outcomes.

Why do ADHD myths persist despite decades of research? In NEI Podcast Episode 275, Drs. Andy Cutler and Tim Wilens tackl...
02/11/2026

Why do ADHD myths persist despite decades of research? In NEI Podcast Episode 275, Drs. Andy Cutler and Tim Wilens tackle the most persistent misconceptions shaping ADHD treatment decisions and replace stigma with data. A must-listen for clinicians navigating patient hesitancy and misinformation. Listen now:

In this episode, Dr. Andy Cutler talks with Dr. Tim Wilens about enduring myths surrounding ADHD diagnosis and treatment, beginning with why misconceptions about overdiagnosis and misuse continue to shape clinical hesitation.

Antipsychotic selection in schizophrenia is a high-stakes decision, yet guidelines offer limited direction on comparativ...
02/10/2026

Antipsychotic selection in schizophrenia is a high-stakes decision, yet guidelines offer limited direction on comparative efficacy. A large head-to-head randomized trial in more than 3,000 hospitalized adults (ages 18–45) with acute exacerbations compared seven antipsychotics over six weeks: olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, perphenazine, and haloperidol. Read more:

Antipsychotic selection in schizophrenia is a high-stakes decision, yet guidelines offer limited direction on comparative efficacy. A large head-to-head randomized trial in more than 3,000 hospitalized adults (ages 18–45) with acute exacerbations compared seven antipsychotics over six weeks: olanz...

Presenting a poster at the NEI Spring Congress Scientific Poster Session allows you to share your research with a nation...
02/03/2026

Presenting a poster at the NEI Spring Congress Scientific Poster Session allows you to share your research with a national audience, strengthen your CV for residency, fellowship, and early-career advancement, engage directly with peers and senior experts in psychiatry, and earn publication in CNS Spectrums with a DOI.
Submit your abstract before the February 6 deadline.

Are you working on research you’re excited to share? The 2026 NEI Spring Congress Scientific Poster Session is your opportunity to present your work on a national stage alongside leaders in psychiatry and mental health

Address

Malvern, PA

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Neuroscience Education Institute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Neuroscience Education Institute:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

Thousands of clinicians consider NEI their top mental health resource for point of care answers and continuing medical education (CME). Here's why:

NEI Prescribe, our prescribing app, features over 140 psychiatric medications and has a dedicated Child and Adolescent section with in-depth coverage of the most commonly prescribed psychotropic drugs in pediatric patients. Continuously updated and with an interactive filter to search for medications based on key drug interactions and side effects, NEI Prescribe is your tool for point of care prescribing.

Our two annual conferences—NEI Congress in the fall and NEI Synapse in the spring—fuse learning, quality, and entertainment into an educational experience that will empower you to provide the best possible care for your patients.

We offer hundreds of online CME activities, including animations, case studies, self-assessments, and encore presentations from NEI's live events.